CXCL12 and acute myeloid leukemia: Taken together, our findings revealed the effect of E5 in inhibiting acute myeloid leukemia cells from responding to CXCL12- or MS-5 induced activation and eradicating leukemia cells in vitro and in vivo, which demonstrate the promising potentiality of E5 in leukemia therapies.